Meeting
2020 ASCO Virtual Scientific Program
Recurrent or metastatic salivary gland tumor (MSGT) patients treated with selinexor, a first in class selective exportin-1 (XPO1) inhibitor.
Authors
Eoghan Ruadh Malone
Princess Margaret Hospital, Toronto, ON, Canada
Eoghan Ruadh Malone , Anna Spreafico , Ilan Weinreb , Sarah Jennings , Lindsay Carlsson , Ahmad Noori , Lisa Wang , Lillian L. Siu , Aaron Richard Hansen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT02069730
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6586)
DOI
10.1200/JCO.2020.38.15_suppl.6586
Abstract #
6586
Poster Bd #
247
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Molecular profiling and targeted agents in recurrent, metastatic salivary gland tumor (R/M SGT) patients (pts) treated at two academic centers.
First Author: Alberto Hernando-Calvo
Poster
2024 ASCO Genitourinary Cancers Symposium
Days spent with healthcare contact by patients with metastatic castrate-resistant prostate cancer in the last year of life.
First Author: Daniel Sentana Lledo
Poster
2022 ASCO Annual Meeting
Outcomes of recurrent and metastatic endometrial cancer (RMEC) treated with systemic progestins.
First Author: Anjali Kulkarni
Poster
2021 ASCO Annual Meeting
Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.
First Author: Neelima Vidula